Digoxin treatment does not reinduce radioiodine uptake in radioiodine refractory non-medullary thyroid carcinoma
European Thyroid Journal · 2024
DOI: 10.1530/etj-24-0153 ↗Kurz gefasst
Fachartikel in der Zeitschrift European Thyroid Journal, 2024. Verfasst von Pepijn van Houten und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Internal Medicine, Division of Endocrinology, Radboud University Medical Center, Nijmegen, the Netherlands. Hauptthemen laut MEDLINE: Digoxin, Iodine Radioisotopes, Thyroid Neoplasms. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 38 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).
Abstract (Originalsprache)
Objective
Patients with non-medullary thyroid carcinoma (NMTC) that are refractory to radioactive iodine (RAI) have a poor prognosis. Strategies for restoring the ability to take up iodine, so-called redifferentiation, are promising but not suitable for all patients. Preclinical studies, in human cell lines just as in a murine model, have shown that the cardiac glycoside digoxin restored RAI uptake. This prospective single-center open-label study aimed to investigate whether treatment with digoxin could reinduce clinically relevant RAI uptake in patients with metastasized RAI-refractory NMTC.
Methods
Eight patients with metastasized RAI-refractory NMTC were included between November 2022 and June 2023. Before treatment, a baseline [ 123 I]NaI scintigraphy was performed. Thereafter, patients were treated with digoxin for 3 weeks. Starting doses depended on age and weight. For safety reasons, the usual therapeutic range was aimed for. After 1 week, the digoxin plasma concentration was measured, and the digoxin dose was adjusted if necessary. After 3 weeks of digoxin treatment, a second [ 123 I]NaI scintigraphy was performed. RAI uptake was compared between the two scintigraphies.
Results
Seven patients completed the digoxin treatment and were evaluable. None of the seven patients showed clinically relevant RAI uptake after digoxin treatment. No digoxin-related serious adverse events occurred during this trial.
Conclusion
Contrary to results from preclinical trials, in this trial, 3 weeks of digoxin treatment did not reinduce RAI uptake in patients with NMTC. This highlights essential challenges regarding the approach toward optimization of studies aimed to restore the RAI uptake and its therapeutic efficacy through drug repurposing.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Internal Medicine, Division of Endocrinology, Radboud University Medical Center, Nijmegen, the Netherlands.
- Roentgeninstitut Duesseldorf, Duesseldorf, Germany.
- Department of Radiology and Nuclear Medicine, Radboud University Medical Center, Nijmegen, the Netherlands.
- Department of Medical Oncology, Radboud University Medical Center, Nijmegen, the Netherlands.
- Department of Pathology, Radboud University Medical Center, Nijmegen, the Netherlands.
- Research Center for Functional Genomics, Biomedicine and Translational Medicine, Iuliu Hatieganu University of Medicine and Pharmacy, Cluj-Napoca, Romania.
ORCID-Profile: Pepijn van Houten
Zitieren
APA
van Houten, P., Nagarajah, J., Walraven, J. E. W., Jaeger, M., van Engen-van Grunsven, A. C. H., Smit, J. W., & Netea-Maier, R. T. (2024). Digoxin treatment does not reinduce radioiodine uptake in radioiodine refractory non-medullary thyroid carcinoma. European Thyroid Journal. https://doi.org/10.1530/etj-24-0153
Vancouver
van Houten P, Nagarajah J, Walraven JEW, Jaeger M, van Engen-van Grunsven ACH, Smit JW, et al. Digoxin treatment does not reinduce radioiodine uptake in radioiodine refractory non-medullary thyroid carcinoma. European Thyroid Journal. 2024. doi:10.1530/etj-24-0153
BibTeX
@article{vanHouten2024,
author = {van Houten, Pepijn and Nagarajah, James and Walraven, Janneke E W and Jaeger, Martin and van Engen-van Grunsven, Adriana C H and Smit, Johannes W and Netea-Maier, Romana T},
title = {Digoxin treatment does not reinduce radioiodine uptake in radioiodine refractory non-medullary thyroid carcinoma},
journal = {European Thyroid Journal},
year = {2024},
doi = {10.1530/etj-24-0153}
}
EUVIMED